# China NMPA Drug Inspection - Anhui Jiezhong Biochemical Co., Ltd. - Chinese herbal medicine slices

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-jiezhong-biochemical-co-ltd/0174ae98-3ee1-414a-8767-9273860f9e7b/
Source feed: China

> China NMPA drug inspection for Anhui Jiezhong Biochemical Co., Ltd. published November 18, 2019. Drug: Chinese herbal medicine slices. The Shandong Provincial Food and Drug Administration (SPFDA) issued an announcement on August 17, 2018, detailing signif

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shandong Provincial Food and Drug Administration Regarding 10 Batches of Drugs Failing Quality Inspection (Issue No. 8, 2018)
- Company Name: Anhui Jiezhong Biochemical Co., Ltd.
- Publication Date: 2019-11-18
- Drug Name: Chinese herbal medicine slices
- Inspection Finding: The quality does not meet the standard requirements.
- Action Taken: Control measures such as sealing, seizure, suspension of sales, and product recall have been taken, and cases have been filed against the relevant production enterprises and sampled units in accordance with relevant laws and regulations.
- Summary: The Shandong Provincial Food and Drug Administration (SPFDA) issued an announcement on August 17, 2018, detailing significant quality control failures for ten batches of pharmaceutical products. Inspections, carried out by multiple drug testing institutions including the Zibo Municipal Institute for Food and Drug Control, revealed that four batches of drugs from three manufacturers, notably Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co., Ltd., and six batches of traditional Chinese medicine decoction pieces from five companies, including Anhui Jiezhong Biochemical Co., Ltd., did not meet established quality standards. In response to these violations, the municipal food and drug administrations have implemented stringent control measures. These include the immediate sealing, seizure, suspension of sales, and recall of all affected substandard products. Additionally, investigations and legal actions have been initiated against the implicated manufacturers and sampled entities. The regulatory framework mandates that these companies thoroughly investigate the underlying causes of the quality issues, formulate and implement effective rectification plans, and proactively eliminate potential risks, reinforcing the administration's commitment to public health and drug safety.

Company: https://www.globalkeysolutions.net/companies/anhui-jiezhong-biochemical-co-ltd/a663a46b-9b30-4e79-90aa-2a48c6be4da9/